We are thrilled to announce Jérôme Vailland’s appointment as 4P-Pharma’s new Chief Financial Officer. Jérôme Vailland built a solid career with significant contributions at Ernst & Young (EY), where he worked for 10+ years. He gained extensive experience in financial audit, company structuring, transactions, and IPOs across European and American markets, mainly in life sciences. Over the years, he held several positions up to Senior Manager, managing and advising numerous clients while assuming broader technical and managerial responsibilities.
Following his strong experience at EY, Jérôme joined Horama, now Coave Therapeutics, in 2016, serving as Chief Financial Officer. He successfully raised funds for the company by leveraging his strategic and leadership skills. In 2020, he became Chief Financial Officer of a biotechnology company listed on the Euronext Paris regulated market, focusing on developing tools and services for genome modification analysis and control.
These positions underscore his deep understanding of the financial challenges faced by public and private biotech companies and the practical solutions that must be implemented to deliver efficient results.
By joining the company’s executive team, Jérôme Vailland will contribute to supporting the company’s growth, especially through effective and transparent financial management. Jérôme Vailland’s recognized finance skills and excellent understanding of organization structuring will be an asset for 4P-Pharma.
Click to read the press release : English version
Click to read the press release : French version
